ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.05 | 4.50 | -0.98 | 4.03 |
| FCF Yield | -0.35% | -8.99% | -11.27% | -14.82% |
| EV / EBITDA | -163.07 | -12.68 | -9.83 | -6.99 |
| Quality | ||||
| ROIC | -17.02% | -39.67% | -34.28% | -31.11% |
| Gross Margin | 97.03% | 86.24% | 89.51% | 88.08% |
| Cash Conversion Ratio | 0.28 | 0.78 | 0.74 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 67.22% | 99.61% | 156.34% | 24.36% |
| Free Cash Flow Growth | 82.67% | 12.12% | 14.45% | -20.88% |
| Safety | ||||
| Net Debt / EBITDA | -1.82 | -0.98 | -0.38 | 0.68 |
| Interest Coverage | -5.74 | -9.08 | -16.10 | -51.99 |
| Efficiency | ||||
| Inventory Turnover | 4.41 | 1.89 | 2.33 | 0.85 |
| Cash Conversion Cycle | -1,034.46 | -403.64 | -1,321.77 | -6,632.83 |